Neutral/Negative Catalysts
- Analyst concern on 2026 growth: Stifel downgrade cites potential moderation from high-margin VA medical exam work; this can cap near-term multiple expansion until proven durable.
- Deal execution/financing risk: planned $2.4B cash acquisition of ENTRUST introduces integration and capital allocation scrutiny.
- Technicals not yet “risk-on”: MACD still below zero and price is below pivot resistance (~190.36), so a clean momentum breakout is not confirmed yet.
- Elevated implied volatility: options market is pricing higher uncertainty into the next 30 days (good for catalysts, but reflects non-trivial event sensitivity).